TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.MoreShow less
Profile & Fundamentals
TransMedics Group: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
TransMedics Group Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Company profile record
TransMedics Group Inc
Common Stock · Health Care · Health Care Equipment
Company
- Company / asset
- TransMedics Group Inc
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Health Care Equipment
- HQ
- 🇺🇸 United States
- Head office
- 200 Minuteman Road, Andover, MA, United States, 01810
Leadership & scale
- Chief executive
- Dr. Waleed H. Hassanein M.D.
- CEO year born
- 1968
- Full-time employees
- 898
- Fiscal year end
- December
- IPO date
- 2019-05-02
Fundamentals snapshot
- Market Cap
- USD 3.5B
- P/E
- 22.9x
- Revenue (Q2 26)
- USD 189.9M
- Profit (Q2 26)
- USD 14.7M
- Dividend Yield
- --
- Revenue (FY 25)
- USD 605.5M
- Shares in public float
- 33.6M
- Insider ownership
- 3.64%
Reporting & identifiers
- Symbol
- TMDX.NASDAQ
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US89377M1099
- Asset ID
- equity_d62d0544-c7ef-5aac-89a3-9c2c26cb704d
Ownership
Shares Outstanding
- Shares outstanding
Top holders
- BlackRock Inc5,293,331 shares · 15.27% · Reported 2026-03-31
- FMR Inc5,096,243 shares · 14.70% · Reported 2026-03-31
- iShares Core S&P Small-Cap ETF2,106,551 shares · 6.08% · Reported 2026-08-31
- Vanguard Portfolio Management, LLC1,919,535 shares · 5.54% · Reported 2026-03-31
- Vanguard Capital Management, LLC1,478,152 shares · 4.26% · Reported 2026-03-31
- State Street Corp1,319,479 shares · 3.81% · Reported 2026-03-31
- Vanguard MStar Total Stk Mkt Idx Invest1,042,917 shares · 3.01% · Reported 2026-07-31
View more holders (8)
- Amvescap Plc.1,037,974 shares · 2.99% · Reported 2026-03-31
- UBS Asset Mgmt Americas Inc939,523 shares · 2.71% · Reported 2026-03-31
- Delaware Management Holdings Inc885,841 shares · 2.55% · Reported 2026-03-31
- iShares Russell 2000 ETF878,107 shares · 2.53% · Reported 2026-08-31
- The Goldman Sachs Group Inc866,282 shares · 2.50% · Reported 2026-03-31
- Geode Capital Management, LLC839,155 shares · 2.42% · Reported 2026-03-31
- Vanguard Small Cap Index754,806 shares · 2.18% · Reported 2026-07-31
- Fidelity Small Cap Growth726,130 shares · 2.09% · Reported 2026-06-30
Earnings, Profitability & Valuation
Earnings & Revenue
Revenue, Net Income, and Free Cash Flow
- Revenue
- Free cash flow
- Net income
Valuation
Historical P/E Ratio
- Published P/E
Profitability & Margins
Profitability Margins
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.